TAGLN3

Chr 3

transgelin 3

Also known as: NP22, NP24, NP25

Predicted to enable actin filament binding activity. Predicted to be involved in actin filament organization. Predicted to act upstream of or within negative regulation of transcription by RNA polymerase II. Predicted to be located in nucleus. Predicted to be active in actin cytoskeleton and synapse. [provided by Alliance of Genome Resources, Apr 2025]

ResearchGenerating clinical summary…

Clinical highlights

Interpreting a novel variant
This gene is strongly intolerant of loss-of-function variation in the population, so LoF variants warrant close attention. No curated mechanism annotation is available — see the mechanism card for the computational prediction and its caveats.Based on population constraint only.
0
Active trials
3
Pubs (1 yr)
P/LP submissions
P/LP missense
0.71
LOEUF
Multiple*
Mechanism· predicted
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.71LOEUF
pLI 0.185
Z-score 2.21
OE 0.28 (0.130.71)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
1.57Z-score
OE missense 0.60 (0.490.73)
71 obs / 119.2 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.28 (0.130.71)
00.351.4
Missense OE?0.60 (0.490.73)
00.61.4
Synonymous OE?0.95
01.21.6
LoF obs/exp: 3 / 10.8Missense obs/exp: 71 / 119.2Syn Z: 0.25

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

TAGLN3 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →